Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors


Creative Commons License

GÖKÇEN K. , Kilicarslan H., Coskun B., ERSOY A., Kaygisiz O., Kordan Y.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, cilt.10, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 10
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5489/cuaj.3170
  • Dergi Adı: CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL

Özet

Introduction: Hormonal, neurogenic, vasculogenic, and psychogenic impairments, as well as endothelial dysfunction may play a role in erectile dysfunction (ED) in patients with chronic kidney disease (CKD). Asymmetrical dimethylarginine (ADMA) is an inhibitor of nitric oxide, which is the key element of ED. ADMA levels are increased in CKD. We aimed to evaluate the effect of serum ADMA, prolactin, testosterone, and hemoglobin levels on erectile function of patients with CKD and control subjects.